Niagen Bioscience, Inc. (NAGE) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly period ended June 30, 2025. Niagen Bioscience, Inc. (formerly ChromaDex Corporation) is a global bioscience company focused on healthy aging, primarily through its proprietary NAD+ precursor, Niagen®. The company operates three segments: Consumer Products (Tru Niagen®), Ingredients (food and pharmaceutical-grade Niagen®), and Analytical Reference Standards and Services. As of August 4, 2025, there were approximately 79.8 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | 6 Months 2025 | 6 Months 2024 |
|---|---|---|---|---|
| Net Sales | $31,117 | $22,739 | $61,598 | $44,892 |
| Gross Profit | $20,226 | $13,693 | $39,557 | $27,149 |
| Gross Margin | 65.0% | 60.2% | 64.2% | 60.5% |
| Operating Income | $3,185 | $(256) | $7,957 | $(987) |
| Net Income | $3,609 | $(15) | $8,672 | $(507) |
| Diluted EPS | $0.04 | $0.00 | $0.10 | $(0.01) |
| Cash & Equivalents | $60,474 (as of June 30, 2025) | |||
| Operating Cash Flow (6mo) | $9,133 (2025) vs $31 (2024) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 37% year-over-year for both the quarter and six-month periods. The Ingredients segment saw the most significant growth (131% for Q2), driven by pharmaceutical-grade Niagen® sales which commenced in late 2024. Consumer Products sales grew 22%, primarily due to e-commerce expansion.
- Profitability: The company transitioned from a net loss in Q2 2024 to a net income of $3.6 million in Q2 2025. Operating income improved from a loss of $256k to a profit of $3.2 million.
- Margin Expansion: Gross margin improved by approximately 480 basis points in Q2 2025 compared to the prior year, attributed to favorable product mix shifts (higher e-commerce proportion) and operational efficiencies.
- Legal Settlement: The company received the final installment of a $2.65 million settlement from Elysium Health in March 2025, recorded as a recovery of credit losses, which significantly impacted the reduction in General and Administrative expenses.
Outlook, Risks, and Unusual Items
- Liquidity: Management anticipates that current cash ($60.5 million) and operating cash flows will meet obligations for the next 12 months. However, the company may seek additional capital for long-term strategic objectives.
- Supply Commitments: In July 2025, the company executed a supply agreement with W.R. Grace & Co.-Conn requiring the purchase of approximately $32.6 million in inventory through July 2026. This creates a significant near-term cash outflow obligation.
- Legal Contingency: While the Elysium California action was settled, a separate Delaware patent infringement action remains on appeal. The company faces a potential contingent liability of approximately $10.4 million (including interest) if the appeal is unsuccessful, though no accrual has been recorded as the outcome is uncertain.
- Customer Concentration: Approximately 71.7% of trade receivables are concentrated among four major customers, including A.S. Watson Group and Life Extension. Sales to A.S. Watson temporarily declined in Q2 2025 but are expected to stabilize.
Investor Verification Checklist
- Supply Chain Dependency: Verify the terms and financial impact of the new exclusive supply agreement with W.R. Grace, specifically the $32.6 million purchase commitment.
- Legal Exposure: Monitor the status of the Delaware patent infringement appeal against Elysium Health and the potential $10.4 million liability.
- Customer Concentration: Assess the stability of relationships with top four customers who represent the majority of trade receivables.
- Pharmaceutical-Grade Growth: Evaluate the sustainability of the rapid growth in the pharmaceutical-grade Niagen® segment, which is a new revenue stream.
- Cash Burn vs. Generation: Confirm that operating cash flow remains positive despite the upcoming inventory purchase obligations.